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Summary Serum CA 15-3 values were determined in 177 patients with primary breast cancer and in 41 with
non-malignant breast disease. Increased preoperative serum CA 15-3 values (>38 Uml-1) were observed in
7%, 17%, 64% and 67% of patients with stage I, II, III and IV disease, respectively and in none of the
patients with benign breast disease. Patients with elevated serum CA 15-3 values had poor 3-year cumulative
survival (27%). In the postoperative follow-up 9% of patients with no clinical evidence of disease, 33% with
a single metastasis and 67% with two or more metastases had elevated values. Increasing or decreasing serum
CA 15-3 values correlated with the clinical outcome in 26 out of 27 cases (96%), whereas serum values
remaining in the reference range had no predictive value. At the time of recurrence elevated serum CA 15-3
values were also observed in patients with normal preoperative values. Increased serum CA 15-3 values
preceeded the clinical detection of tumour recurrence by up to 13 months. In conclusion, serum CA 15-3
levels had prognostic value in breast cancer, reflected the extent of clinically detectable disease and the
presence of occult metastatic disease. Further research is warranted on the benefits of CA 15-3 assays in
relation to adjuvant chemotherapy as well as the earlier detection and treatment of metastatic disease.
The value of clinical laboratory tests in the follow-up of
breast cancer patients has been questioned due to their
insensitivity and nonspecificity (Ormiston et al., 1985; Tomin
& Donegan, 1987). CEA has been the only tumour marker
suitable in some cases for the monitoring of treatment in
advanced breast cancer (Tormey & Waalkes, 1978; Mughal
et al., 1983). More sensitive and specific serum markers are
required in the detection of tumour recurrence and in the
monitoring of treatment response.
A radioimmunometric assay based on two different
monoclonal antibodies (115 D8 and DF3) has been intro-
duced for a breast cancer-associated antigen CA 15-3 (Kufe
et al., 1984; Hilkens et al., 1984). Preliminary clinical
evidence indicates that in the follow-up of breast cancer
CA 15-3 is more sensitive than CEA (Hayes et al., 1986;
Wurz et al., 1986; Pons-Anicet et al., 1987). In the present
study we evaluated the sensitivity and specificity of CA 15-3
and the use of this assay in the follow-up of breast cancer
patients.
Materials and methods
Serum samples were collected from 177 patients with prim-
ary breast cancer and from 58 age-adjusted patients with
nonmalignant breast disease. All patients were operated in
the Tampere University Central Hospital in 1981-1985. Both
preoperative and postoperative (1-3 year follow-up) serum
samples were obtained from 68 patients. The samples were
stored at -70°C for 1-6 years before analysis. The patients
were staged according to the TNM classification. In the
postoperative period judgement of the presence or absence of
tumour was based on clinical examination, chest and bone
radiographs and in a few cases isotope scans.
Serum CA 15-3 levels were determined using an immuno-
radiometric assay kit (ELSA-CA 15-3, International CIS,
Cedex, France). The reference range for serum CA 15-3 level
was determined on the basis of values obtained from patients
with non-malignant breast diseases (Mean+3 s.d.).
Results
The upper reference value for normal CA 15-3 value was set
at 38 Uml-. In the preoperative period, markedly elevated
serum CA 15-3 values were observed mainly in patients with
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locally advanced (stage III) and metastatic (stage IV) breast
cancer (Figure 1). None of the patients with benign breast
tumours or breast infections had elevated serum values.
Short-term follow-up (median 1.9 years) of the patients
indicated 27% cumulative 3-year survival for cases with
elevated preoperative serum CA 15-3 levels as compared to
84% for patients with normal serum levels (P<0.001,
Mantel-Cox test). Since this analysis was based on small
numbers of patients with elevated values and short follow-up
time it was not possible to determine whether CA 15-3 values
had prognostic value independent of the TNM staging.
In serum samples obtained 1-5 years after operation
CA 15-3 again showed a good correlation with clinical
disease status (Figure 2). About two-thirds of the patients
with several metastases had elevated serum CA 15-3 values.
One-third of the patients with a single (in most cases
locoregional) metastasis and only 9% of patients with no
clinical evidence of disease had increased serum values. One
patient had markedly elevated serum CA 15-3 value without
any clinical evidence of disease (Figure 2). At the time of
blood sampling this patient apparently had subclinical dis-
ease because 13 months later an intra-abdominal breast
cancer metastasis was diagnosed (Figure 3).
Follow-up of the patients disclosed that serum values
remaining in the reference range did not give reliable infor-
> 500 *
300
250
CY)
L6 cU
:
n
200
150
100
50
7% 17% 64% 67%
:1- X* -00
... --:: I., * :--: ::- : i
Stage II III IV Fibrocystic Other Inf. Control
;:, , , disease ben. breast patients
LOs (nI= 21) tumors disease (n = 17)
11 11 11 iI(n= 15) (n= 5)
Breast cancer
Figure 1 Preoperative serum CA 15-3 values in patients with
breast cancer and other non-malignant breast diseases. The
percentage of patients having increased serum values is shown.
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Figure 2 Serum CA 15-3 values 1 5 years after operation
according to clinical disease status. The percentage of patients
with elevated serum values is shown.
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Figure 4 Relation of serum CA 15-3 levels with disease course
in a patient with primary breast cancer. Serum CA 15-3 levels
raised concomitantly with the detection of multiple bone, liver
and lung metastasis (Dg), which rapidly lead to the death (D) of
the patient.
Table I Relation of disease course to changes in serum CA 15-3
levels. If only those patients who at some stage of the disease had
elevated serum CA 15-3 levels were included in the table (figures in
parentheses), changes in serum CA 15-3 levels paralleled clinical
disease course in 26/27 cases (96%)
Serum CA 15-3 values
Remain in the
reference range Increase Decrease
No evidence of cancer 19 (0) -
Progression of cancer 21 (1) 19 (19)
Regression of cancer - - 7 (7)
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Figure 3 Relation of serum CA 15-3 levels with disease course
in a patient operated for primary breast cancer. Elevated serum
CA 15-3 values preceeded the clinical diagnosis (Dg) of intra-
abdominal carcinomatosis by 13 months. Following combination
chemotherapy and antiestrogen treatment (Th) complete clinical
response was obtained with concomitant decrease of serum
CA 15-3 levels to the reference range.
mation on changes of tumour mass of the patients. However,
if only those patients with increasing or decreasing serum
levels were considered, changes in serum CA 15-3 concent-
ration paralleled the clinical course of the disease in 26 out
of 27 (96%) cases (Table I) during a 1-3 year follow-up
period (Figures 3 and 4). At the time of recurrence elevated
serum CA 15-3 values were also observed in patients with
normal preoperative values.
Discussion
In patients with various breast diseases CA 15-3 values
higher than 38 Uml-1 appeared to be highly specific for
cancer. Previous investigators have reported elevated values
ranging from 5% (Wurz et al., 1986) to 22% (Hayes et al.,
1986) in benign breast diseases, using 30Uml-P as the cut-
off level. Hayes et al. (1986) have also detected elevated
values in 1/16 (6%) of lactating women and in 20-80% of
malignancies other than breast cancer. In our study the
higher cut-off value was based on the analysis of samples
from patients with benign breast diseases and enabled us to
achieve higher specificity without notable decrease in
sensitivity.
Both the present and previous investigations (Wurz et al.,
1986; Pons-Anicet et al., 1987) indicate that increased pre-
operative values of CA 15-3 are observed mainly in patients
with advanced breast cancer and not in the more common
early-stage tumours. Therefore, the sensitivity of the assay
does not allow use of CA 15-3 as a sole diagnostic or
prognostic test for breast cancer. The present preliminary
results indicated that elevated preoperative values may have
prognostic significance. Whether serum CA 15-3 values add
independent information to the prognostic assessment of
breast cancer or merely reflect tumour burden similar to
TNM-staging remains to be determined. It would be advan-
tageous to incorporate measurements of serum CA 15-3
levels in adjuvant therapy trials. In this regard the critical
issue is, whether serum CA 15-3 values are raised in micro-
metastatic disease, or only in advanced macrometastatic
disease, where adjuvant therapy is no more indicated. On the
basis of the clinicopathological correlations of CA 15-3, the
latter possibility appears more likely, although only a follow-
up study of stage I-II breast cancer patients with elevated
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preoperative serum CA 15-3 levels will give data in this
respect.
At the time of metastasis elevated serum CA 15-3 values
were also observed in patients who had normal preoperative
levels. In fact, about two-thirds of patients with more than
one metastasis had elevated values. It thus seems that in the
postoperative monitoring of disease recurrence all patients
and not only those with elevated preoperative values may
benefit from this assay. However, both the present and
previous (Hayes et al., 1986; Wurz et al., 1986; Pons-Anicet
et al., 1987) results suggest that serum CA 15-3 assay is not
very sensitive in detecting a single locoregional metastasis.
In the follow-up of the patients increasing and decreasing
serum CA 15-3 values have more clinical significance than
values remaining in the reference range. It should also be
noted that patients may have progressing disease in spite of
persistently low serum CA 15-3 levels. In the present study
we demonstrated that serum CA 15-3 values may be elevated
up to 13 months prior to the clinical diagnosis of residive.
Apparently disease-free patients with elevated serum CA 15-3
values may therefore have occult metastasis. Due to the slow
disease progression in breast cancer, with metastases occur-
ring up to 15-20 years (Sutherland & Mather, 1986; Harris
& Hellman, 1986) after initial treatment, the chances of
detecting such subclinical metastases are considerable. How-
ever, at the time being there is no evidence indicating that
the earlier detection of metastatic disease by serial tumour
marker assays is beneficial in terms of gained survival time.
Further research on subclinical metastatic breast disease and
CA 15-3 levels is warranted before elevated serum levels
could justify immediate therapeutic intervention.
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